Despite adjuvant chemotherapy, TNBC patients have the greatest likelihood of relapse within 1 to 3 years.[4,70] Some researchers administered doxorubicin and XBP1 shRNA to MDA-MB-231 xenograft-bearing mice to study the impact of XBP1 on tumor relapse after chemotherapeutic treatment. Here, XBP1 is linked to neoplasm.